These compounds may interact with:
Neuropeptide Y receptor type 1
Potentially involved in: carcinoma; obesity; anxiety disorders; depressive disorder; neural tube defects; psychoses, substance-induced; psychotic disorders; schizophrenia; toothache; amphetamine-related disorders; nonorganic psychosis; active ulcerative colitis; adrenocortical carcinoma; adult high grade glioma; astrocytic glioma; astrocytoma, pilocytic; atypical teratoid / rhabdoid tumor; breast cancer; cystic fibrosis and chronic rhinosinusitis; ductal carcinoma in situ
Disease data sourced from Pharos.